Researchers conducted a cohort study to compare lung cancer risk among patients with COPD and T2DM using SGLT2 inhibitors vs sulfonylureas.

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...

Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 52 weeks, patients receiving dupilumab vs. placebo ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people globally ...

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a ...

In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according to a study presented at CHEST 2024, the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...